Friday Aug 29
Today's Market: Red Hot Biotech And Big Pharma Names To Watch
A busy week is about to come to an end, but not before we have learned a lot about the strength of this market and just how resilient it is.
Thu Aug 28, 2014
When Will M&A Come To The Hepatitis C Space?
Biotech InterMune was taken out by Roche for over $8 billion yesterday in a deal that had an almost 40% buyout premium.
Wed Aug 27, 2014
Gilead Sciences: Due For More Short Squeezing?
Short sellers of Gilead Sciences must be starting to sweat a bit as the stock continues its impressive trajectory: However, the short interest figures just came out for the first half of August and they in fact show that about 8 million shares were covered in that time period.
Tue Aug 26, 2014
Biotech Stocks: Time to Worry
I mean, just look at these returns: Gilead Sciences has gained 41% so far this year as investors appear to have put their Sovaldi worries behind them ; InterMune has quintupled in 2014 after Roche agreed to purchase it for $8.3 billion ; and Intercept Pharmaceuticals has surged 350% as drug trials have been surprisingly good .
Gilead Sciences: Despite This Year's Triumphs, Watch Out For Weaknesses - An Algorithmic Perspective
Gilead Sciences, a pharmaceuticals company specializing in drug discovery, development, and commercialization, has seen considerable success recently: its strong first- and second-quarter results make its 2014 analyst rating primarily bullish.
Mon Aug 25, 2014
Us Stocks-S&P 500 tops 2,000 for first time in broad advance
The S&P 500 stock index rose to an intraday record on Monday, topping 2,000 for the first time in a broad rally led by financial and biotechnology stocks.
Sat Aug 23, 2014
RBC Capital Increases Gilead Sciences Price Target to $115.00
The firm currently has an "outperform" rating on the stock. RBC Capital's price target points to a potential upside of 10.62% from the company's current price.
Thu Aug 21, 2014
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Wed Aug 20, 2014
Recent Analysts' Ratings Updates for Gilead Sciences
A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.
Fri Aug 15, 2014
Gilead: Rising Short Interest Provides Yet Another Reason To Own The Stock
Its forward P/E is low relative to the market, thus incorporating caution about the sustainability of profits from its hepatitis C franchise.
Silicon Alley Insider
Biotech Stock Achillion Is Soaring After Good News About Its Hepatitis C Drug
Achillion Pharmaceuticals was up more than 11% on Friday after the company announced positive interim results for its hepatitis C treatment.
Gilead: More Good News For This Biotech Juggernaut
Highlighted below is my rebuttal to a recent short thesis on Gilead and why is stock is still cheap and going much higher.
Tue Aug 12, 2014
Cramer's Lightning Round - El Pollo Loco Is Acting Crazy
StoneMor Partners : "I don't understand why it yields 10%. That would usually be a red flag, but I like StoneMor."
Wed Aug 06, 2014
Zacks Downgrades Gilead Sciences to Neutral
They currently have a $97.00 target price on the stock. Zacks 's price objective suggests a potential upside of 5.13% from the stock's previous close.
Mon Aug 04, 2014
Blue Shield of California CEO: Hepatitis C pill shows drug pricing is 'broken'
The head of Blue Shield of California on Monday said Gilead Sciences' controversial hepatitis C drug is unsustainable at $1,000 a day, joining a growing chorus of payers who are unhappy with the price.
Why Gilead Sciences Stock Is Still A Great Investment Opportunity
Gilead has compelling valuation metrics and exceptional earnings growth prospects; its PEG ratio of 0.41, is the lowest among all S&P 500 companies.
Sun Aug 03, 2014
New FDA process speeds approval of high-priced breakthrough drugs
This undated file handout photo provided by Gilead Sciences shows the hepatitis C medication Sovaldi.